Induction Chemotherapy and Adjuvant Thoracic Radiation in Resectable Stage N2-3A/3B Non-small Cell Lung Cancer (ICAT study)
- Conditions
- Resectable Stage 3A-N2 Non-small Cell Lung Cancer
- Registration Number
- JPRN-UMIN000025010
- Lead Sponsor
- Kyoto Prefectural University of Medicine
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 1
Not provided
1.Evident unresectable extranodal lymph node involvement in CT scanning 2.Contraindication to either carboplatin or nab-paclitaxel 3.History of severe drug hypersensitivity 4.Impaired pulmonary function 5.Myocardial infarction within 6 months (180 days) prior to consent 6.Interstitial pneumonia, pulmonary fibrosis suspected or diagnosed within 56 days prior to consent 7.Administration of prednisolone > 10mg/day within 90 days prior to consent 8.Clinically severe heart diseases 9.Clinically severe psychiatric diseases 10.Uncontrollable diabetes mellitus 11.Clinically active infection 12.Any other severe complication 13.Active double malignancies 14.Pregnant, lactating or possibly pregnant 15.Any other unsuitable reasons judged by attending investigators
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method feasibility
- Secondary Outcome Measures
Name Time Method response rate of induction chemotherapy, safety, progression free survival